+ Performance-based incentives
Hybrid position based in New Prague, Minnesota; candidates must live within commuting distance.
Electromed, Inc. designs, manufactures, and markets medical devices that provide airway clearance therapy. Its flagship product, the SmartVest Airway Clearance System, uses high frequency chest wall oscillation (HFCWO) to help people clear excess mucus from the lungs, aiding those with impaired airway clearance. The system is designed for home and clinical use, delivering oscillating pressure to the chest to loosen and move mucus so it can be coughed out. The company differentiates itself by focusing specifically on airway clearance technology and offering a hands-on commitment to service, framed by its mission to help people breathe better and live more active, fulfilling lives. Electromed’s goal is to make life’s important moments possible—one breath at a time.
Company Size
201-500
Company Stage
IPO
Headquarters
New Prague, Minnesota
Founded
1992
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?
Unlimited Paid Time Off
401(k) Company Match
Health Insurance
Health Savings Account/Flexible Spending Account
Disability Insurance
Parental Leave
Wellness Program
Training Programs
Professional Development Budget
Tuition Reimbursement
Electromed Inc (ELMD) is scheduled to release its Q4 2026 earnings on 25 August 2026. Analysts expect quarterly revenue of $19.33 million and earnings of $0.32 per share. For the full year 2026, revenue is forecast at $73.60 million with earnings of $1.22 per share. These estimates have remained unchanged over the past 90 days. In the previous quarter, Electromed beat revenue expectations by 6.04% and earnings estimates by 44.03%, posting actual revenue of $18.58 million and earnings of $0.35 per share. The stock rose 25.11% following the results. Three analysts have set an average one-year price target of $40.33, suggesting 2.24% upside from the current price of $39.45. However, GuruFocus estimates a fair value of $29.08, implying 26.29% downside. The average brokerage recommendation is "outperform".
Electromed, a Minnesota-based airway clearance technology company, reported record financial results for its fiscal 2026 third quarter ended March 31. Net revenues increased 18.4% to $18.6 million, driven by an 18.6% rise in its core homecare market. Operating income surged 76.0% to a record $3.8 million, representing 20.3% of net revenues. Net income reached $3.0 million, or $0.35 per diluted share, up 58.8% year-over-year. The results marked Electromed's 14th consecutive quarter of year-over-year revenue and profit growth. The company ended the quarter with $17.0 million in cash, $28.3 million in accounts receivable, and no debt. CEO Jim Cunniff cited strategic investments in sales teams and 86% coverage of US lives under contract as positioning the company for continued growth.
Electromed, a leader in airway clearance technologies, reported record financial results for its fiscal 2026 second quarter ended 31 December 2025. Net revenues increased 16.3% to $18.9 million, driven by an 18.4% rise in its core homecare market. Operating income reached a record $3.6 million, up 42.4% year-over-year, whilst operating margin improved to 19.2% of net revenues. Net income rose 40.3% to $2.8 million, or $0.32 per diluted share. The company repurchased $2.8 million of common stock at an average price of $26.16 per share during the quarter and ended with $13.8 million in cash and no debt. This marks Electromed's 13th consecutive quarter of year-over-year revenue and net income growth.
Electromed entered a new senior secured revolving credit facility with BMO Bank for $10 million, maturing December 16, 2026 at one-month Term SOFR plus 1.75%. The facility is secured by a first-priority lien on substantially all assets and includes customary and financial covenants, including a min…
Electromed, Inc. ("Electromed" or the "Company") (NYSE American: ELMD), a leader in innovative airway clearance technologies, today announced that Company management will participate in the Canaccord Genuity 45 [th] Annual Growth Conference, which will be held August 12-14, 2025 in Boston, MA.